SETBP1 mutations drive leukemic transformation in ASXL1-mutated MDS

Leukemia

Volumn 29, Issue 4, 2015, Pages 847-857

  Inoue, D ^a   Kitaura, J ^a   Matsui, H ^b   Hou, H A ^c   Chou, W C ^c   Nagamachi, A ^b   Kawabata, K C ^a   Togami, K ^a   Nagase, R ^a   Horikawa, S ^a   Saika, M ^a   Micol, J B ^d   Hayashi, Y ^a   Harada, Y ^e   Harada, H ^e   Inaba, T ^b   Tien, H F ^c   Abdel Wahab, O ^d   Kitamura, T ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b HIROSHIMA UNIVERSITY   (Japan)

^c NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^e JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BINDING PROTEIN; CANCER GROWTH FACTOR; PHOSPHOPROTEIN PHOSPHATASE 2A; PROTEIN KINASE B; SET BINDING PROTEIN 1; TUMOR GROWTH FACTOR BETA; UNCLASSIFIED DRUG; ASXL1 PROTEIN, HUMAN; CARRIER PROTEIN; HOMEODOMAIN PROTEIN; HOXA PROTEIN; NUCLEAR PROTEIN; PHOSPHOPROTEIN PHOSPHATASE 2; REPRESSOR PROTEIN; SETBP1 PROTEIN, HUMAN; TRANSFORMING GROWTH FACTOR BETA;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; ASXL1 GENE; CONTROLLED STUDY; DIFFERENTIATION; ENZYME ACTIVITY; FEMALE; GENE; GENE EXPRESSION; GENE MUTATION; HOXA GENE; HUMAN; HUMAN CELL; IN VIVO STUDY; MAJOR CLINICAL STUDY; MOUSE; MYELODYSPLASTIC SYNDROME; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; SETBP1 GENE; STEM CELL; SURVIVAL; UBIQUITINATION; ACUTE MYELOBLASTIC LEUKEMIA; ANIMAL; C57BL MOUSE; CELL DIFFERENTIATION; CELL TRANSFORMATION; GENE EXPRESSION REGULATION; GENETICS; HEK293 CELL LINE; HL 60 CELL LINE; METABOLISM; MORTALITY; MUTATION; PATHOLOGY; SIGNAL TRANSDUCTION; SURVIVAL ANALYSIS;

ADULT; ANIMALS; APOPTOSIS; CARRIER PROTEINS; CELL DIFFERENTIATION; CELL TRANSFORMATION, NEOPLASTIC; GENE EXPRESSION REGULATION, LEUKEMIC; HEK293 CELLS; HL-60 CELLS; HOMEODOMAIN PROTEINS; HUMANS; LEUKEMIA, MYELOID, ACUTE; MICE; MICE, INBRED C57BL; MUTATION; MYELODYSPLASTIC SYNDROMES; NUCLEAR PROTEINS; PROTEIN PHOSPHATASE 2; PROTEOLYSIS; PROTO-ONCOGENE PROTEINS C-AKT; REPRESSOR PROTEINS; SIGNAL TRANSDUCTION; SURVIVAL ANALYSIS; TRANSFORMING GROWTH FACTOR BETA; UBIQUITINATION;

EID: 84927699006     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2014.301     Document Type: Article

References (59)

1. Raza A, Galili N. The genetic basis of phenotypic heterogeneity in myelodysplastic syndromes. Nat Rev Cancer 2012; 12: 849-859.
2. Nimer SD. Myelodysplastic syndromes. Blood 2008; 111: 4841-4851.
3. Cazzola M, Della Porta MG, Malcovati L. The genetic basis of myelodysplasia and its clinical relevance. Blood 2013; 122: 4021-4034.
4. Papaemmanuil E, Gerstung M, Malcovati L, Tauro S, Gundem G, Van Loo P et al. Clinical and biological implications of driver mutations in myelodysplastic syndromes. Blood 2013; 122: 3616-3627.
5. Bejar R, Levine R, Ebert BL. Unraveling the molecular pathophysiology of myelodysplastic syndromes. J Clin Oncol 2011; 29: 504-515.
6. Delhommeau F, Dupont S, Della Valle V, James C, Trannoy S, Massé A et al. Mutation in TET2 in myeloid cancers. N Engl J Med 2009; 360: 2289-2301.
7. Langemeijer SM, Kuiper RP, Berends M, Knops R, Aslanyan MG, Massop M et al. Acquired mutations in TET2 are common in myelodysplastic syndromes. Nat Genet 2009; 41: 838-842.
8. Bejar R, Stevenson K, Abdel-Wahab O, Galili N, Nilsson B, Garcia-Manero G et al. Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med 2011; 364: 2496-2506.
9. Bejar R, Stevenson KE, Caughey BA, Abdel-Wahab O, Steensma DP, Galili N et al. Validation of a prognostic model and the impact of mutations in patients with lower-risk myelodysplastic syndromes. J Clin Oncol 2012; 30: 3376-3382.
10. Yoshida K, Sanada M, Shiraishi Y, Nowak D, Nagata Y, Yamamoto R et al. Frequent pathway mutations of splicing machinery in myelodysplasia. Nature 2011; 478: 64-69.
11. Graubert TA, Shen D, Ding L, Okeyo-Owuor T, Lunn CL, Shao J et al. Recurrent mutations in the U2AF1 splicing factor in myelodysplastic syndromes. Nat Genet 2012; 44: 53-57.
12. Kon S, Minegishi N, Tanabe K, Watanabe T, Funaki T, Wong WF et al. Smap1 deficiency perturbs receptor trafficking and predisposes mice to myelodysplasia. J Clin Invest 2013; 123: 1123-1137.
13. Yamazaki J, Issa JP. Epigenetic aspects of MDS and its molecular targeted therapy. Int J Hematol 2013; 97: 175-182.
14. Inoue D, Kitaura J, Togami K, Nishimura K, Enomoto Y, Uchida T et al. Myelodysplastic syndromes are induced by histone methylation-altering ASXL1 mutations. J Clin Invest 2013; 123: 4627-4640.
15. Muto T, Sashida G, Oshima M, Wendt GR, Mochizuki-Kashio M, Nagata Y et al. Concurrent loss of Ezh2 and Tet2 cooperates in the pathogenesis of myelodysplastic disorders. J Exp Med 2013; 210: 2627-2639.
16. Abdel-Wahab O, Adli M, LaFave LM, Gao J, Hricik T, Shih AH et al. ASXL1 mutations promote myeloid transformation through loss of PRC2-mediated gene repression. Cancer Cell 2012; 22: 180-193.
17. Abdel-Wahab O, Gao J, Adli M, Dey A, Trimarchi T, Chung YR et al. Deletion of Asxl1 results in myelodysplasia and severe developmental defects in vivo. J Exp Med 2013; 210: 2641-2659.
18. Li Z, Cai X, Cai CL, Wang J, Zhang W, Petersen BE et al. Deletion of Tet2 in mice leads to dysregulated hematopoietic stem cells and subsequent development of myeloid malignancies. Blood 2011; 118: 4509-4518.
19. Moran-Crusio K, Reavie L, Shih A, Abdel-Wahab O, Ndiaye-Lobry D, Lobry C et al. Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation. Cancer Cell 2011; 20: 11-24.
20. Wang J, Li Z, He Y, Pan F, Chen S, Rhodes S et al. Loss of Asxl1 leads to myelodysplastic syndrome-like disease in mice. Blood 2014; 123: 541-553.
21. Gelsi-Boyer V, Brecqueville M, Devillier R, Murati A, Mozziconacci MJ, Birnbaum D. Mutations in ASXL1 are associated with poor prognosis across the spectrum of malignant myeloid diseases. J Hematol Oncol 2012; 5: 12.
22. Chen TC, Hou HA, Chou WC, Tang JL, Kuo YY, Chen CY et al. Dynamics of ASXL1 mutation and other associated genetic alterations during disease progression in patients with primary myelodysplastic syndrome. Blood Cancer J 2014; 4: E177.
23. Thol F, Friesen I, Damm F, Yun H, Weissinger EM, Krauter J et al. Prognostic significance of ASXL1 mutations in patients with myelodysplastic syndromes. J Clin Oncol 2011; 29: 2499-2506.
24. Meggendorfer M, Bacher U, Alpermann T, Haferlach C, Kern W, Gambacorti-Passerini C et al. SETBP1 mutations occur in 9% of MDS/MPN and in 4% of MPN cases and are strongly associated with atypical CML, monosomy 7, isochromosome i(17)(q10), ASXL1 and CBL mutations. Leukemia 2013; 27: 1852-1860.
25. Makishima H, Yoshida K, Nguyen N, Przychodzen B, Sanada M, Okuno Y et al. Somatic SETBP1 mutations in myeloid malignancies. Nat Genet 2013; 45: 942-946.
26. Hou HA, Kuo YY, Tang JL, Chou WC, Yao M, Lai YJ et al. Clinical implications of the SETBP1 mutation in patients with primary myelodysplastic syndrome and its stability during disease progression. Am J Hematol 2014; 89: 181-186.
27. Haferlach T, Nagata Y, Grossmann V, Okuno Y, Bacher U, Nagae G et al. Landscape of genetic lesions in 944 patients with myelodysplastic syndromes. Leukemia 2014; 28: 241-247.
28. Thol F, Suchanek KJ, Koenecke C, Stadler M, Platzbecker U, Thiede C et al. SETBP1 mutation analysis in 944 patients with MDS and AML. Leukemia 2013; 27: 2072-2075.
29. Piazza R, Valletta S, Winkelmann N, Redaelli S, Spinelli R, Pirola A et al. Recurrent SETBP1 mutations in atypical chronic myeloid leukemia. Nat Genet 2013; 45: 18-24.
30. Cristóbal I, Garcia-Orti L, Cirauqui C, Alonso MM, Calasanz MJ, Odero MD. PP2A impaired activity is a common event in acute myeloid leukemia and its activation by forskolin has a potent anti-leukemic effect. Leukemia 2011; 25: 606-614.
31. Cristóbal I, Blanco FJ, Garcia-Orti L, Marcotegui N, Vicente C, Rifon J et al. SETBP1 overexpression is a novel leukemogenic mechanism that predicts adverse outcome in elderly patients with acute myeloid leukemia. Blood 2010; 115: 615-625.
32. Oakley K, Han Y, Vishwakarma BA, Chu S, Bhatia R, Gudmundsson KO et al. Setbp1 promotes the self-renewal of murine myeloid progenitors via activation of Hoxa9 and Hoxa10. Blood 2012; 119: 6099-6108.
33. Gelsi-Boyer V, Trouplin V, Adélaïde J, Bonansea J, Cervera N, Carbuccia N et al. Mutations of polycomb-associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia. Br J Haematol 2009; 145: 788-800.
34. Nakahara F, Sakata-Yanagimoto M, Komeno Y, Kato N, Uchida T, Haraguchi K et al. Hes1 immortalizes committed progenitors and plays a role in blast crisis transition in chronic myelogenous leukemia. Blood 2010; 115: 2872-2881.
35. Akashi K, Traver D, Miyamoto T, Weissman IL. A clonogenic common myeloid progenitor that gives rise to all myeloid lineages. Nature 2000; 404: 193-197.
36. Watanabe-Okochi N, Kitaura J, Ono R, Harada H, Harada Y, Komeno Y et al. AML1 mutations induced MDS and MDS/AML in a mouse BMT model. Blood 2008; 111: 4297-4308.
37. Kitamura T, Koshino Y, Shibata F, Oki T, Nakajima H, Nosaka T et al. Retrovirusmediated gene transfer and expression cloning: Powerful tools in functional genomics. Exp Hematol 2003; 31: 1007-1014.
38. Enomoto Y, Yamanishi Y, Izawa K, Kaitani A, Takahashi M, Maehara A et al. Characterization of leukocyte mono-immunoglobulin-like receptor 7 (LMIR7)/CLM-3 as an activating receptor: Its similarities to and differences from LMIR4/CLM-5. J Biol Chem 2010; 285: 35274-35283.
39. Kimura H, Hayashi-Takanaka Y, Goto Y, Takizawa N, Nozaki N. The organization of histone H3 modifications as revealed by a panel of specific monoclonal antibodies. Cell Struct Funct 2008; 33: 61-73.
40. Neviani P, Santhanam R, Trotta R, Notari M, Blaser BW, Liu S et al. The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABL-regulated SET protein. Cancer Cell 2005; 8: 355-368.
41. Raza A, Mundle S, Shetty V, Alvi S, Chopra H, Span L et al. Novel insights into the biology of myelodysplastic syndromes: Excessive apoptosis and the role of cytokines. Int J Hematol 1996; 63: 265-278.
42. Raza A, Gezer S, Mundle S, Gao XZ, Alvi S, Borok R et al. Apoptosis in bone marrow biopsy samples involving stromal and hematopoietic cells in 50 patients with myelodysplastic syndromes. Blood 1995; 86: 268-276.
43. Parker J, Fishlock K, Mijovic A, Czepulkowski B, Pagliuca A, Mufti G. 'Low-risk' myelodysplastic syndrome is associated with excessive apoptosis and an increased ratio of pro-versus anti-apoptotic bcl-2-related proteins. Br J Haematol 1998; 103: 1075-1082.
44. Hengartner MO. The biochemistry of apoptosis. Nature 2000; 407: 770-776.
45. Parker J, Mufti G, Rasool F, Mijovic A, Devereux S, Pagliuca A. The role of apoptosis, proliferation, and the Bcl-2-related proteins in the myelodysplastic syndromes and acute myeloid leukemia secondary to MDS. Blood 2000; 96: 3932-3938.
46. Kita-Sasai Y, Horiike S, Misawa S, Kaneko H, Kobayashi M, Nakao M et al. International prognostic scoring system and TP53 mutations are independent prognostic indicators for patients with myelodysplastic syndrome. Br J Haematol 2001; 115: 309-312.
47. Sablina AA, Hahn WC. The role of PP2A A subunits in tumor suppression. Cell Adh Migr 2007; 1: 140-141.
48. Arnold HK, Sears RC. A tumor suppressor role for PP2A-B56alpha through negative regulation of c-Myc and other key oncoproteins. Cancer Metast Rev 2008; 27: 147-158.
49. Krivtsov AV, Twomey D, Feng Z, Stubbs MC, Wang Y, Faber J et al. Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9. Nature 2006; 442: 818-822.
50. Calvo KR, Sykes DB, Pasillas M, Kamps MP. Hoxa9 immortalizes a granulocytemacrophage colony-stimulating factor-dependent promyelocyte capable of biphenotypic differentiation to neutrophils or macrophages, independent of enforced meis expression. Mol Cell Biol 2000; 20: 3274-3285.
51. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA et al. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 2005; 102: 15545-15550.
52. Dong M, Blobe GC. Role of transforming growth factor-beta in hematologic malignancies. Blood 2006; 107: 4589-4596.
53. Jakubowiak A, Pouponnot C, Berguido F, Frank R, Mao S, Massague J et al. Inhibition of the transforming growth factor beta 1 signaling pathway by the AML1/ETO leukemia-associated fusion protein. J Biol Chem 2000; 275: 40282-40287.
54. Lin HK, Bergmann S, Pandolfi PP. Cytoplasmic PML function in TGF-beta signalling. Nature 2004; 431: 205-211.
55. Imai Y, Kurokawa M, Izutsu K, Hangaishi A, Maki K, Ogawa S et al. Mutations of the Smad4 gene in acute myelogeneous leukemia and their functional implications in leukemogenesis. Oncogene 2001; 20: 88-96.
56. Hoffman B, Amanullah A, Shafarenko M, Liebermann DA. The proto-oncogene c-myc in hematopoietic development and leukemogenesis. Oncogene 2002; 21: 3414-3421.
57. Koinuma D, Tsutsumi S, Kamimura N, Taniguchi H, Miyazawa K, Sunamura M et al. Chromatin immunoprecipitation on microarray analysis of Smad2/3 binding sites reveals roles of ETS1 and TFAP2A in transforming growth factor beta signaling. Mol Cell Biol 2009; 29: 172-186.
58. Frederick JP, Liberati NT, Waddell DS, Shi Y, Wang XF. Transforming growth factor beta-mediated transcriptional repression of c-myc is dependent on direct binding of Smad3 to a novel repressive Smad binding element. Mol Cell Biol 2004; 24: 2546-2559.
59. Zhou L, Nguyen AN, Sohal D, Ying Ma J, Pahanish P, Gundabolu K et al. Inhibition of the TGF-beta receptor I kinase promotes hematopoiesis in MDS. Blood 2008; 112: 3434-3443.